文献速递烧伤创面修复

CytoSorb®用于烧伤脓毒性休克合并急性肾损伤并接受连续性肾脏替代治疗的患者与临床结局和生存改善相关

CytoSorb® in burn patients with septic shock and Acute Kidney Injury on Continuous Kidney Replacement Therapy is associated with improved clinical outcome and survival.
PubMed 文献 · Burns · 2024-03-01

意大利都灵烧伤中心2017年1月至2022年12月回顾性观察35例因急性肾损伤相关脓毒性休克接受连续性肾脏替代治疗的严重烧伤患者,其中11例联合CytoSorb®、24例仅用连续性肾脏替代治疗。联合组去甲肾上腺素用量显著减少,住院死亡率45.4%对70.8%,270天Kaplan-Meier生存分析显著更优(p=0.0445)。

要点

  • 11例联合CytoSorb®者住院死亡率45.4%,24例仅连续性肾脏替代治疗者70.8%。
  • 联合组去甲肾上腺素用量较对照组显著减少,存活与未存活者第4天较第1天显著下降。
  • 270天Kaplan-Meier生存分析联合组显著更优(p=0.0445)。

核心结论

  • 对标准治疗反应不佳的烧伤合并急性肾损伤-连续性肾脏替代治疗及脓毒性休克患者,CytoSorb®辅助治疗带来显著临床改善,并与较单纯连续性肾脏替代治疗更低的死亡率相关。

研究设计与样本

  • 意大利都灵烧伤中心2017年1月至2022年12月的回顾性观察研究,纳入35例因急性肾损伤相关脓毒性休克接受连续性肾脏替代治疗的严重烧伤患者。
  • 35例中11例在连续性肾脏替代治疗基础上联合CytoSorb®(吸附组),24例仅接受连续性肾脏替代治疗(对照组)。

主要发现

  • 11例中7例在开始连续性肾脏替代治疗的同时启动吸附剂应用,CytoSorb®的应用方式非常分散。
  • 吸附组去甲肾上腺素用量较对照组显著减少。
  • 吸附组存活与未存活患者均在CytoSorb®治疗前4天观察到临床改善,第4天去甲肾上腺素用量较第1天显著下降。
  • 住院死亡率吸附组为45.4%、对照组为70.8%,270天Kaplan-Meier生存分析显著更优(p=0.0445)。
  • 两组存活患者出院时均恢复肾功能,未存活患者均未恢复。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In burn patients, septic shock and acute kidney injury (AKI) with use of continuous renal replacement therapy (CRRT) severely increase morbidity and mortality. Sorbent therapies could be an adjunctive therapy to address the underlying metabolic changes in inflammatory and anti-inflammatory cytokines dysregulated production. METHODS: A retrospectively observational study of 35 severe burn patients admitted to the Burn Center (Turin, Italy, from January 2017 to December 2022), who underwent CRRT for AKI-associated septic shock. Out of 35 patients, 11 were treated with CytoSorb® as adjunctive therapy to CRRT (Sorbent group) and 24 patients only with CRRT (Control group). RESULTS: The application of CytoSorb® took place in a very dispersed way. Out of 11 patients, 7 started the CRRT together with the sorbent application. The patients of the sorbent group exhibited a significant reduction in norepinephrine use compared to that of the control group. A clinical improvement over the first 4 days of Cytosorb® was observed in both survivors and no survivors of the sorbent group, with significant norepinephrine decreased use on day 4 compared to day 1. In-hospital mortality was 45.4% and 70.8% in the sorbent and control group, respectively, and significantly better at Kaplan-Meier survival analysis at 270 days (p = 0.0445). In both groups, all survivor patients recovered renal function at discharge, whereas no survivors did not. CONCLUSIONS: Adjunctive treatment with CytoSorb® for burn patients with AKI-CRRT and septic shock poorly responsive to standard therapy led to a significant clinical improvement, and was associated with a lower mortality rate compared to CRRT alone.

来源:Burns,查看原文。版权归原作者所有。

引用

  1. Mariano F, Greco' D, Depetris N, et al. CytoSorb® in burn patients with septic shock and Acute Kidney Injury on Continuous Kidney Replacement Therapy is associated with improved clinical outcome and survival. Burns. 2024. PMID: 38494395. doi:10.1016/j.burns.2024.02.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。